Mathai Mammen
CIK 1421050 · EVP, Pharm, R&D · last filed 2024-06-13
Mathai Mammen is an EVP, Pharm, R&D who has filed 63 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for TXG, was dated Jun 13, 2024. Across all open-market trades the lifetime net is −$4.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $20.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$20.90M
4
63
-$4.70M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TXG | Director | 180,259 | $28.84 | $5.20M | -$1.74M | 7 | 2024-06-13 |
| JNJ | EVP, Pharm, R&D | 45,300 | $240.87 | $10.91M | $0 | 2 | 2022-02-17 |
| TBPH | SVP, Research & Development | 288,111 | $16.64 | $4.79M | $0 | 10 | 2016-03-17 |
| Innoviva, Inc. (THRX) Delisted | SVP, Research & Early Clin Dev | 334,040 | $4.06 | $1.36M | -$2.96M | 44 | 2014-08-22 |
Recent Filings
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-13 | TXG | Grant (A) | +8,649 | $0 | EDGAR |
| 2023-06-16 | TXG | Grant (A) | +1,865 | $0 | EDGAR |
| 2023-05-15 | TXG | Mixed | +167,000 | -$1.51M | EDGAR |
| 2022-06-17 | TXG | Grant (A) | +2,120 | $0 | EDGAR |
| 2022-02-17 | JNJ | Mixed | +4,374 | -$558.4K | EDGAR |
| 2022-02-15 | JNJ | Mixed | +5,083 | -$394.3K | EDGAR |
| 2021-06-15 | TXG | Grant (A) | +625 | $0 | EDGAR |
| 2020-06-17 | TXG | Grant (A) | — | $0 | EDGAR |
| 2019-09-16 | TXG | Other (J) | — | $0 | EDGAR |
| 2016-03-17 | TBPH | Grant (A) | +90,000 | $0 | EDGAR |